AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
norethindrone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1963 | 51-98-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Acetate ester of norethindrone that is used as a long-term contraceptive (CONTRACEPTIVE AGENTS).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.63 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 30, 1973 | FDA | WARNER CHILCOTT LLC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic adenoma | 214.83 | 15.97 | 37 | 8446 | 402 | 90619562 |
| Vaginal haemorrhage | 197.93 | 15.97 | 83 | 8400 | 31188 | 90588776 |
| Heavy menstrual bleeding | 148.59 | 15.97 | 60 | 8423 | 20470 | 90599494 |
| Endometriosis | 138.20 | 15.97 | 42 | 8441 | 6206 | 90613758 |
| Pelvic pain | 108.08 | 15.97 | 44 | 8439 | 15313 | 90604651 |
| Hot flush | 102.98 | 15.97 | 66 | 8417 | 59422 | 90560542 |
| Prostatic disorder | 75.08 | 15.97 | 11 | 8472 | 36 | 90619928 |
| Intermenstrual bleeding | 63.43 | 15.97 | 26 | 8457 | 9197 | 90610767 |
| Aplastic anaemia | 60.52 | 15.97 | 28 | 8455 | 13241 | 90606723 |
| Borderline serous tumour of ovary | 53.09 | 15.97 | 7 | 8476 | 7 | 90619957 |
| Metaplasia | 48.66 | 15.97 | 11 | 8472 | 510 | 90619454 |
| Purpura | 45.90 | 15.97 | 24 | 8459 | 14754 | 90605210 |
| Haemorrhage | 44.86 | 15.97 | 43 | 8440 | 69326 | 90550638 |
| Mood swings | 40.90 | 15.97 | 25 | 8458 | 20677 | 90599287 |
| Menstruation irregular | 39.87 | 15.97 | 18 | 8465 | 8042 | 90611922 |
| Dysmenorrhoea | 38.48 | 15.97 | 15 | 8468 | 4657 | 90615307 |
| Adnexal torsion | 37.79 | 15.97 | 9 | 8474 | 525 | 90619439 |
| Ovarian cyst | 37.02 | 15.97 | 22 | 8461 | 17296 | 90602668 |
| Abdominal pain | 32.67 | 15.97 | 96 | 8387 | 395625 | 90224339 |
| Nasal mucosal discolouration | 29.68 | 15.97 | 5 | 8478 | 47 | 90619917 |
| Rash maculo-papular | 25.75 | 15.97 | 25 | 8458 | 40908 | 90579056 |
| Menstrual disorder | 25.05 | 15.97 | 12 | 8471 | 6126 | 90613838 |
| Pulmonary embolism | 24.58 | 15.97 | 44 | 8439 | 130776 | 90489188 |
| Dermatitis atopic | 24.20 | 15.97 | 19 | 8464 | 23453 | 90596511 |
| Arthropathy | 24.03 | 15.97 | 3 | 8480 | 366239 | 90253725 |
| Rash erythematous | 23.95 | 15.97 | 30 | 8453 | 65074 | 90554890 |
| Migraine | 23.76 | 15.97 | 54 | 8429 | 190338 | 90429626 |
| Acne | 22.97 | 15.97 | 20 | 8463 | 28487 | 90591477 |
| Abnormal uterine bleeding | 22.18 | 15.97 | 8 | 8475 | 2004 | 90617960 |
| Transfusion | 22.13 | 15.97 | 16 | 8467 | 17472 | 90602492 |
| Surgery | 22.05 | 15.97 | 24 | 8459 | 44863 | 90575101 |
| Product administration interrupted | 21.94 | 15.97 | 14 | 8469 | 12478 | 90607486 |
| Abnormal withdrawal bleeding | 21.72 | 15.97 | 4 | 8479 | 65 | 90619899 |
| Post viral fatigue syndrome | 21.60 | 15.97 | 5 | 8478 | 258 | 90619706 |
| Uterine leiomyoma | 21.15 | 15.97 | 13 | 8470 | 10851 | 90609113 |
| Hepatic rupture | 20.84 | 15.97 | 4 | 8479 | 82 | 90619882 |
| Superior sagittal sinus thrombosis | 20.33 | 15.97 | 6 | 8477 | 800 | 90619164 |
| Haemoglobin decreased | 20.28 | 15.97 | 46 | 8437 | 161910 | 90458054 |
| Uterine spasm | 20.11 | 15.97 | 6 | 8477 | 831 | 90619133 |
| Contraindicated product administered | 20.10 | 15.97 | 3 | 8480 | 320136 | 90299828 |
| Uterine pain | 19.74 | 15.97 | 5 | 8478 | 377 | 90619587 |
| Abdominal distension | 19.69 | 15.97 | 40 | 8443 | 130561 | 90489403 |
| Melaena | 19.57 | 15.97 | 20 | 8463 | 34777 | 90585187 |
| Blood iron decreased | 19.52 | 15.97 | 15 | 8468 | 17944 | 90602020 |
| Coronary artery dissection | 19.34 | 15.97 | 6 | 8477 | 948 | 90619016 |
| Irritability | 19.16 | 15.97 | 20 | 8463 | 35642 | 90584322 |
| Peliosis hepatis | 19.07 | 15.97 | 4 | 8479 | 130 | 90619834 |
| Menopausal symptoms | 18.88 | 15.97 | 8 | 8475 | 3070 | 90616894 |
| Depression | 18.49 | 15.97 | 66 | 8417 | 300535 | 90319429 |
| Pregnancy on oral contraceptive | 18.42 | 15.97 | 6 | 8477 | 1109 | 90618855 |
| Haemorrhagic tumour necrosis | 18.24 | 15.97 | 3 | 8480 | 24 | 90619940 |
| Intracranial pressure increased | 18.17 | 15.97 | 10 | 8473 | 6801 | 90613163 |
| Mood altered | 17.94 | 15.97 | 14 | 8469 | 17130 | 90602834 |
| Exposure to allergen | 17.93 | 15.97 | 5 | 8478 | 545 | 90619419 |
| Tympanic membrane perforation | 17.31 | 15.97 | 7 | 8476 | 2390 | 90617574 |
| Crying | 16.76 | 15.97 | 16 | 8467 | 25629 | 90594335 |
| Treatment failure | 16.64 | 15.97 | 4 | 8479 | 303924 | 90316040 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hepatic adenoma | 231.09 | 18.03 | 37 | 6236 | 430 | 110582596 |
| Vaginal haemorrhage | 200.64 | 18.03 | 69 | 6204 | 25005 | 110558021 |
| Metaplasia | 132.43 | 18.03 | 24 | 6249 | 603 | 110582423 |
| Heavy menstrual bleeding | 119.17 | 18.03 | 42 | 6231 | 16323 | 110566703 |
| Endometriosis | 95.49 | 18.03 | 26 | 6247 | 4308 | 110578718 |
| Prostatic disorder | 94.14 | 18.03 | 23 | 6250 | 2486 | 110580540 |
| Pelvic pain | 72.54 | 18.03 | 29 | 6244 | 15913 | 110567113 |
| Hot flush | 63.38 | 18.03 | 42 | 6231 | 65994 | 110517032 |
| Borderline serous tumour of ovary | 55.66 | 18.03 | 7 | 6266 | 9 | 110583017 |
| Intermenstrual bleeding | 55.10 | 18.03 | 19 | 6254 | 6915 | 110576111 |
| Aplastic anaemia | 54.75 | 18.03 | 27 | 6246 | 24281 | 110558745 |
| Adnexal torsion | 44.10 | 18.03 | 9 | 6264 | 427 | 110582599 |
| Purpura | 43.07 | 18.03 | 23 | 6250 | 24365 | 110558661 |
| Ovarian cyst | 35.98 | 18.03 | 17 | 6256 | 13913 | 110569113 |
| Menstruation irregular | 35.15 | 18.03 | 13 | 6260 | 5784 | 110577242 |
| Dysmenorrhoea | 33.04 | 18.03 | 11 | 6262 | 3599 | 110579427 |
| Haemorrhage | 30.80 | 18.03 | 34 | 6239 | 106658 | 110476368 |
| Mood swings | 30.70 | 18.03 | 18 | 6255 | 22794 | 110560232 |
| Borderline ovarian tumour | 30.63 | 18.03 | 5 | 6268 | 66 | 110582960 |
| Nasal mucosal discolouration | 29.97 | 18.03 | 5 | 6268 | 76 | 110582950 |
| Haemorrhagic tumour necrosis | 25.26 | 18.03 | 4 | 6269 | 43 | 110582983 |
| Rash erythematous | 25.22 | 18.03 | 27 | 6246 | 81805 | 110501221 |
| Uterine leiomyoma | 24.80 | 18.03 | 11 | 6262 | 7789 | 110575237 |
| Abnormal withdrawal bleeding | 24.56 | 18.03 | 4 | 6269 | 52 | 110582974 |
| Transfusion | 23.94 | 18.03 | 16 | 6257 | 25456 | 110557570 |
| Post viral fatigue syndrome | 23.67 | 18.03 | 5 | 6268 | 281 | 110582745 |
| Blood iron decreased | 22.85 | 18.03 | 14 | 6259 | 19200 | 110563826 |
| Genital haemorrhage | 22.33 | 18.03 | 10 | 6263 | 7242 | 110575784 |
| Migraine | 22.19 | 18.03 | 37 | 6236 | 171615 | 110411411 |
| Abdominal pain | 21.57 | 18.03 | 71 | 6202 | 512918 | 110070108 |
| Superior sagittal sinus thrombosis | 21.18 | 18.03 | 6 | 6267 | 1147 | 110581879 |
| Hepatic rupture | 20.60 | 18.03 | 4 | 6269 | 147 | 110582879 |
| Death | 20.59 | 18.03 | 7 | 6266 | 698862 | 109884164 |
| Rash maculo-papular | 20.29 | 18.03 | 23 | 6250 | 74199 | 110508827 |
| Exposure to allergen | 20.28 | 18.03 | 5 | 6268 | 560 | 110582466 |
| Throat tightness | 20.01 | 18.03 | 16 | 6257 | 33473 | 110549553 |
| Acne | 20.00 | 18.03 | 16 | 6257 | 33504 | 110549522 |
| Abnormal uterine bleeding | 19.84 | 18.03 | 6 | 6267 | 1441 | 110581585 |
| Peliosis hepatis | 19.53 | 18.03 | 4 | 6269 | 193 | 110582833 |
| Off label use | 19.33 | 18.03 | 148 | 6125 | 1500037 | 109082989 |
| Dermatitis atopic | 19.22 | 18.03 | 14 | 6259 | 25527 | 110557499 |
| Haemoglobin decreased | 19.10 | 18.03 | 43 | 6230 | 248684 | 110334342 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA CS | M0447349 | Progesterone Congeners |
| FDA Chemical/Ingredient | N0000011301 | Progesterone Congeners |
| MeSH PA | D000080066 | Contraceptive Agents, Hormonal |
| MeSH PA | D003271 | Contraceptive Agents, Female |
| MeSH PA | D012102 | Reproductive Control Agents |
| MeSH PA | D003278 | Contraceptives, Oral, Hormonal |
| MeSH PA | D003280 | Contraceptives, Oral, Synthetic |
| FDA EPC | N0000175602 | Progestin |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:49326 | synthetic oral contraceptive |
| CHEBI has role | CHEBI:59826 | progestin |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Contraception | indication | 13197004 | |
| Dysfunctional uterine bleeding | indication | 19155002 | |
| Secondary physiologic amenorrhea | indication | 86030004 | |
| Acne vulgaris | indication | 88616000 | |
| Uterine fibroids | indication | 95315005 | DOID:13223 |
| Endometriosis | indication | 129103003 | |
| Amenorrhea | off-label use | 14302001 | DOID:13938 |
| Female hypogonadism syndrome | off-label use | 16041008 | |
| Polycystic ovaries | off-label use | 69878008 | |
| Dysmenorrhea | off-label use | 266599000 | |
| Abnormal uterine bleeding unrelated to menstrual cycle | off-label use | 312984006 | |
| Menorrhagia | off-label use | 386692008 | |
| Heart valve disorder | contraindication | 368009 | DOID:4079 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Depressive disorder | contraindication | 35489007 | |
| Migraine | contraindication | 37796009 | DOID:6364 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Body fluid retention | contraindication | 43498006 | |
| Thrombosis of retinal vein | contraindication | 46085004 | |
| Chronic heart failure | contraindication | 48447003 | |
| Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
| Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
| Benign mammary dysplasia | contraindication | 57993004 | |
| Obstructive hyperbilirubinemia | contraindication | 59848001 | |
| Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
| Intermenstrual bleeding - irregular | contraindication | 64996003 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Malignant neoplasm of liver | contraindication | 93870000 | DOID:3571 |
| Deep venous thrombosis | contraindication | 128053003 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Angina pectoris | contraindication | 194828000 | |
| Asthma | contraindication | 195967001 | DOID:2841 |
| Cerebrovascular accident | contraindication | 230690007 | |
| Pulmonary thromboembolism | contraindication | 233935004 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Cholestasis of pregnancy | contraindication | 235888006 | |
| Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
| Pregnancy, function | contraindication | 289908002 | |
| Hypertriglyceridemia | contraindication | 302870006 | |
| Functional visual loss | contraindication | 313165001 | |
| Malignant tumor of cervix | contraindication | 363354003 | DOID:4362 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Obesity | contraindication | 414916001 | DOID:9970 |
| Estrogen receptor positive tumor | contraindication | 416053008 | |
| Porphyria | contraindication | 418470004 | |
| Optic disc edema | contraindication | 423341008 | DOID:146 |
| Hypertensive urgency | contraindication | 443482000 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Major Surgery with Prolonged Post-Operative Immobilization | contraindication | ||
| Nonspecific Abnormal Papanicolaou Smear of Cervix | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01MG,0.01MG;1MG,N/A | LO LOESTRIN FE | APIL | N022501 | Oct. 21, 2010 | RX | TABLET | ORAL | 7704984 | Feb. 2, 2029 | LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION |
| 0.01MG,0.01MG,N/A;1MG,N/A,N/A | LO MINASTRIN FE | APIL | N204654 | July 24, 2013 | DISCN | TABLET, CHEWABLE, TABLET | ORAL | 7704984 | Feb. 2, 2029 | PREVENTION OF PREGNANCY |
| 1MG;0.5MG;40MG | MYFEMBREE | SUMITOMO PHARMA AM | N214846 | May 26, 2021 | RX | TABLET | ORAL | 11033551 | Sept. 29, 2037 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN |
| 1MG;0.5MG;40MG | MYFEMBREE | SUMITOMO PHARMA AM | N214846 | May 26, 2021 | RX | TABLET | ORAL | 11957684 | Sept. 29, 2037 | MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN |
| 1MG;0.5MG;40MG | MYFEMBREE | SUMITOMO PHARMA AM | N214846 | May 26, 2021 | RX | TABLET | ORAL | 11793812 | May 3, 2038 | MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 1MG;0.5MG;40MG | MYFEMBREE | SUMITOMO PHARMA AM | N214846 | May 26, 2021 | RX | TABLET | ORAL | Jan. 27, 2026 | INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF MVT-601-035 |
| 0.02MG;1MG | FEMLYV | MILLICENT MFG PR | N218718 | July 22, 2024 | RX | TABLET, ORALLY DISINTEGRATING | ORAL | July 22, 2027 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Progesterone receptor | Nuclear hormone receptor | AGONIST | ED50 | 11.26 | WOMBAT-PK | CHEMBL | |||
| Glucocorticoid receptor | Nuclear hormone receptor | Ki | 6.53 | DRUG MATRIX | |||||
| Estrogen receptor | Nuclear hormone receptor | Ki | 6.64 | CHEMBL | |||||
| Androgen receptor | Nuclear hormone receptor | IC50 | 7.12 | WOMBAT-PK | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
| Sex hormone-binding globulin | Secreted | Kd | 7.97 | CHEMBL | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.62 | CHEMBL | |||||
| Androgen receptor | Transcription factor | Ki | 7.15 | DRUG MATRIX | |||||
| Progesterone receptor | Transcription factor | Ki | 8.44 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| D00953 | KEGG_DRUG |
| 4018495 | VANDF |
| 4018496 | VANDF |
| C0068980 | UMLSCUI |
| CHEBI:7628 | CHEBI |
| CHEMBL1201146 | ChEMBL_ID |
| D000077563 | MESH_DESCRIPTOR_UI |
| 5832 | PUBCHEM_CID |
| 9S44LIC7OJ | UNII |
| 215496 | RXNORM |
| 182290 | MMSL |
| 2712 | MMSL |
| 41718 | MMSL |
| 5187 | MMSL |
| 5188 | MMSL |
| d00555 | MMSL |
| 001298 | NDDF |
| 001299 | NDDF |
| 001326 | NDDF |
| 005925 | NDDF |
| 126102009 | SNOMEDCT_US |
| 126104005 | SNOMEDCT_US |
| 63758001 | SNOMEDCT_US |
| C0028356 | UMLSCUI |
| DB00717 | DRUGBANK_ID |
| 6230 | PUBCHEM_CID |
| 687 | INN_ID |
| D009640 | MESH_DESCRIPTOR_UI |
| CHEBI:7627 | CHEBI |
| 9S44LIC7OJ | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Jinteli | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-3122 | TABLET | 1 mg | ORAL | ANDA | 29 sections |
| Mimvey | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-5455 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 30 sections |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7274 | TABLET | 1.50 mg | ORAL | ANDA | 21 sections |
| NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-7280 | TABLET | 1 mg | ORAL | ANDA | 22 sections |
| Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0555-0211 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
| Junel21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9025 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
| Junel21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0555-9027 | TABLET | 1.50 mg | ORAL | ANDA | 15 sections |
| Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-650 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
| Norethindrone Acetate and Ethinyl Estradiol | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-6782 | TABLET | 1 mg | ORAL | ANDA | 16 sections |
| Estradiol / Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-8003 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 32 sections |
| Estradiol and Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-8004 | TABLET | 0.10 mg | ORAL | ANDA | 27 sections |
| Norethindrone acetate | Human Prescription Drug Label | 1 | 50742-267 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
| Estradiol and Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50742-657 | TABLET | 0.50 mg | ORAL | ANDA | 27 sections |
| Estradiol and Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50742-658 | TABLET | 0.10 mg | ORAL | ANDA | 27 sections |
| Loestrin21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51285-127 | TABLET | 1.50 mg | ORAL | ANDA | 15 sections |
| Loestrin21 Day | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51285-131 | TABLET | 1 mg | ORAL | ANDA | 15 sections |
| Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-599 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
| Estradiol / Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51991-474 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 33 sections |
| Estradiol / Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51991-623 | TABLET, FILM COATED | 0.10 mg | ORAL | ANDA | 33 sections |
| MICROGESTIN 1/20 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53002-1549 | TABLET | 1 mg | ORAL | NDA AUTHORIZED GENERIC | 21 sections |
| Estradiol / Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-4677 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 25 sections |
| femhrt | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-4679 | TABLET | 1 mg | ORAL | NDA | 20 sections |
| Microgestin | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6213 | TABLET | 1 mg | ORAL | ANDA | 24 sections |
| JINTELI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6251 | TABLET | 1 mg | ORAL | ANDA | 25 sections |
| Junel 1.5/30 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6272 | TABLET | 1.50 mg | ORAL | ANDA | 23 sections |
| Etyqa | Human Prescription Drug Label | 2 | 59651-424 | TABLET, FILM COATED | 0.50 mg | ORAL | ANDA | 29 sections |
| Etyqa | Human Prescription Drug Label | 2 | 59651-425 | TABLET, FILM COATED | 0.10 mg | ORAL | ANDA | 29 sections |
| Norethindrone Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-921 | TABLET | 5 mg | ORAL | ANDA | 21 sections |
| Activella | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60846-231 | TABLET, FILM COATED | 0.10 mg | ORAL | NDA | 28 sections |
| Activella | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60846-232 | TABLET, FILM COATED | 0.50 mg | ORAL | NDA | 28 sections |